Defendant
3 cases as defendant.
Jazz sued Tris Pharma over Tris's January 2026 Section 505(b)(2) NDA for generic Xyrem/Xywav; this docket lists the '426 patent among asserted patents and also lists '400, '181, '494, '446, '306, and '302. The matter appears active.
Second Tris Pharma complaint filed after Tris's Jan 2026 notices of 505(b)(2) NDAs for Xyrem/Xywav generics. The narrative lists it among '306-family actions, though only 2:26-cv-01739 is expressly noted as identifying the '306 patent.
Jazz Pharmaceuticals Ireland Ltd. sued Tris Pharma, Inc. in the District of New Jersey. Judge Stanley R. Chesler denied Tris's motion to dismiss on July 8, 2026, and an answer, counterclaim, and scheduling order followed.